Blood pressure in treated hypertensive individuals with the mthfr 677tt genotype is responsive to intervention with riboflavin: Findings of a targeted randomized trial

Hypertension

Volumn 61, Issue 6, 2013, Pages 1302-1308

  Wilson, Carol P ^a   McNulty, Helene ^a   Ward, Mary ^a   Strain, J J ^a   Trouton, Tom G ^b   Hoeft, Birgit A ^d   Weber, Peter ^d   Roos, Franz F ^d   Horigan, Geraldine ^a   McAnena, Liadhan ^a   Scott, John M ^c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ANTRIM AREA HOSPITAL   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

blood pressure; hypertension; MTHFR; personalized medicine; riboflavin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); PLACEBO; RIBOFLAVIN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE;

BLOOD PRESSURE; HYPERTENSION; MTHFR; PERSONALIZED MEDICINE; RIBOFLAVIN;

AGED; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RIBOFLAVIN; VITAMIN B COMPLEX;

EID: 84878927079     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.01047     Document Type: Article

References (37)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42: 1206-1252.
2. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371: 1513-1518. (Pubitemid 351626187)
3. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 356: 1955-1964.
4. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336: 1121-1123. (Pubitemid 351731743)
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665.
6. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997; 336: 1117-1124.
7. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003; 289: 2083-2093. (Pubitemid 37430210)
8. Kurtz TW. Genome-wide association studies will unlock the genetic basis of hypertension: con side of the argument. Hypertension. 2010; 56: 1021-1025.
9. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009; 41: 677-687.
10. Global BPgen Consortium. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009; 41: 666-676.
11. Niu WQ, You YG, Qi Y. Strong association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension and hypertension-inpregnancy in Chinese: A meta-analysis. J Hum Hypertens. 2012; 26: 259-267.
12. Wilcken B, Bamforth F, Li Z, et al. Geographical and ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003; 40: 619-625. (Pubitemid 37046918)
13. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10: 111-113.
14. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol. 1999; 6: 359-365. (Pubitemid 29166485)
15. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A. 2001; 98: 14853-14858. (Pubitemid 34013934)
16. McNulty H, Dowey le RC, Strain JJ, Dunne A, Ward M, Molloy AM, McAnena LB, Hughes JP, Hannon-Fletcher M, Scott JM. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation. 2006; 113: 74-80. (Pubitemid 43958491)
17. Horigan G, McNulty H, Ward M, Strain JJ, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C->T polymorphism in MTHFR. J Hypertens. 2010; 28: 478-486.
18. Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, Purvis J, Scott JM. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: A 4-y followup. Am J Clin Nutr. 2012; 95: 766-772.
19. National Institute for Health and Clinical Excellence. Management of Hypertension in Adults in Primary Care. London, UK: Royal College of Physicians; 2004.
20. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. Clin Chem. 1999; 45: 569-571. (Pubitemid 29165970)
21. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol. 1997; 281: 43-53. (Pubitemid 27362441)
22. Powers HJ, Bates CJ, Prentice AM, Lamb WH, Jepson M, Bowman H. The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. Hum Nutr Clin Nutr. 1983; 37: 413-425. (Pubitemid 14183953)
23. Heux S, Morin F, Lea RA, Ovcaric M, Tajouri L, Griffiths LR. The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res. 2004; 27: 663-667. (Pubitemid 39534508)
24. Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet. 2007; 15: 1239-1245. (Pubitemid 350143180)
25. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49: 69-75. (Pubitemid 46360343)
26. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. (Pubitemid 35472129)
27. Spurgeon D. NIH promotes use of lower cost drugs for hypertension. BMJ. 2004; 328: 539.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-1762. (Pubitemid 28269185)
29. Institute for Health and Clinical Excellence. Partial Update: Management of Hypertension in Adults in Primary Care Costing Report Implementing NICE Guidance in England. London, UK: Royal College of Physicians. 2006.
30. Fagard R. Reappraisal of the European guidelines on hypertension management: the European Society of Hypertension Task Force document: A short review. Pol Arch Med Wewn. 2010; 120: 31-35.
31. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005; 365: 217-223. (Pubitemid 40138015)
32. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O'Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. Arch Intern Med. 2001; 161: 1183-1192. (Pubitemid 32691515)
33. Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. A cooperative study. J Am Med Assoc. 1977; 237: 255-261.
34. Turner ST, Schwartz GL, Boerwinkle E. Personalized medicine for high blood pressure. Hypertension. 2007; 50: 1-5. (Pubitemid 46985999)
35. Antoniades C, Shirodaria C, Warrick N, Shijie C, DeBono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006; 114: 1193-1201. (Pubitemid 44386484)
36. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, Refsum H, Channon KM. MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009; 119: 2507-2515.
37. Wilson CP, McNulty H, Scott JM, Strain JJ, Ward M. The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proc Nutr Soc. 2010; 69: 156-165.